Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
BioNTech SE ( (BNTX) ) has provided an update.
BioNTech SE has announced that the FDA has lifted the partial clinical hold on its Phase 3 trial for BNT316/ONC-392, a treatment for metastatic non-small cell lung cancer, enabling the continuation of patient enrollment specifically for the squamous NSCLC population. This decision follows prior trial data assessments which indicated differences in patient responses, underscoring BioNTech’s commitment to advancing targeted cancer therapies and potentially improving treatment outcomes.
More about BioNTech SE
BioNTech SE is a biotechnology company based in Mainz, Germany, focused on developing and manufacturing immunotherapies. It specializes in innovative cancer treatments and vaccines, leveraging cutting-edge technology to enhance immune responses against various diseases.
YTD Price Performance: 14.35%
Average Trading Volume: 981,842
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $28.93B
See more data about BNTX stock on TipRanks’ Stock Analysis page.
